

Amendments to and Listing of the Claims:

Please cancel claims 21, 28-30, 32, 33, 38, 39, 50-53, and 55-58, without prejudice.

Please amend claims 20, 31, 34, 35, 40, 41, 49 and 54, without prejudice, as set forth in the following listing of the claims, where deleted language is stricken through or surrounded by double brackets and inserted language is underlined.

Please add new claims 59-66, as set forth in the following listing of the claims.

1. to 6. (Cancelled)

7. (Previously presented) A composition as claimed in claim 34, wherein the cyclodextrin is hydroxypropyl- β -cyclodextrin.

8. to 19. (Cancelled)

20. (Currently Amended) A method of treating a patient in need of treatment with fexofenadine or a pharmaceutically acceptable salt thereof which comprises administering an effective amount of a composition according to claim 34 to an eye ~~or nose~~ of a patient in need of such treatment.

21. to 30. (Cancelled)

31. (Currently Amended) A method of treating a patient in need of a treatment with fexofenadine or a pharmaceutically acceptable salt thereof, the method comprising administering an effective amount of the composition according to claim 35 to an eye ~~or nose~~ of a patient in need of such treatment.

32. and 33. (Cancelled)

34. (Currently Amended) A composition consisting essentially of

- (i) fexofenadine or a pharmaceutically acceptable salt thereof ~~and~~,
- (ii) a pharmaceutical excipient that increases the solubility of the fexofenadine or salt in water selected from the group consisting of a cyclodextrin, and glycofurol, and
- (iii) ~~optionally, a gelling agent or a bioadhesive material~~ thickening agent,

which composition is adapted for delivery of the fexofenadine or pharmaceutically acceptable salt thereof to the eye ~~or nose~~.

35. (Currently Amended) A composition comprising

(i) fexofenadine or a pharmaceutically acceptable salt thereof in an amount selected from the group consisting of 100 µg/ml to 100 mg/ml and 0.5% to 40% wt/wt ~~and,~~

(ii) a pharmaceutical excipient that increases the solubility of the fexofenadine or salt in water selected from the group consisting of a cyclodextrin, and glycofurol, and

(iii) a thickening agent,

which composition is adapted for delivery of the fexofenadine or pharmaceutically acceptable salt thereof to the eye ~~or nose~~.

36. (Previously presented) The composition of claim 35, wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin.

37. (Previously presented) The composition of claim 35, wherein the composition further comprises an aqueous vehicle.

38. and 39. (Cancelled)

40. (Currently amended) An aqueous composition consisting essentially of

(i) fexofenadine or a pharmaceutically acceptable salt thereof;

(ii) a pharmaceutical excipient that increases the solubility of the fexofenadine or salt in water selected from the group consisting of a cyclodextrin[[,]] and glycofurol, ~~and~~

(iii) a thickening agent, and

(iv) an aqueous vehicle,

which composition is adapted for delivery of the fexofenadine or pharmaceutically acceptable salt thereof to the eye ~~or nose~~.

41. (Currently amended) An aqueous composition comprising
- (i) fexofenadine or a pharmaceutically acceptable salt thereof in an amount selected from the group consisting of 100 µg/ml to 100 mg/ml and 0.5% to 40% wt/wt,
 - (ii) a pharmaceutical excipient that increases the solubility of the fexofenadine or salt in water selected from the group consisting of a cyclodextrin[[,]] and glycofurol,
~~and~~
 - (iii) a thickening agent, and
 - (iv) an aqueous vehicle,

which composition is adapted for delivery of the fexofenadine or pharmaceutically acceptable salt thereof to the eye-~~or nose~~.

42. (Previously Presented) The composition of claim 40, wherein the concentration of the pharmaceutical excipient (ii) is 0.5 to 50% w/v.

43. (Previously presented) The composition of claim 41, wherein the concentration of the pharmaceutical excipient (ii) is 0.5 to 50% w/v.

44. (Previously presented) The composition of claim 34, wherein the composition is in the form of a powder formulation and the pharmaceutical excipient (ii) is a cyclodextrin.

45. (Previously presented) The composition of claim 44, wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin.

46. (Previously presented) The composition of claim 35, wherein the composition is in the form of a powder formulation and the pharmaceutical excipient (ii) is a cyclodextrin.

47. (Previously presented) The composition of claim 45, wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin.

48. (Previously presented) The composition according to claim 40, wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin.

49. (Currently Amended) A method of treating a patient in need of treatment with fexofenadine or a pharmaceutically acceptable salt thereof comprising administering an effective amount of a composition of claim 40 to an eye ~~or nose~~ of the patient.

50. to 53. (Cancelled)

54. (Currently Amended) A method of treating a patient in need of a treatment with fexofenadine or a pharmaceutically acceptable salt thereof comprising administering an effective amount of the composition of claim 41 to an eye ~~or nose~~ of the patient.

55. to 58. (Cancelled)

59. (Newly Added) A composition according to claim 34, wherein the thickening agent is selected from the group consisting of polyvinylalcohol and hypromellose.

60. (Newly Added) A composition according to claim 35, wherein the thickening agent is selected from the group consisting of polyvinylalcohol and hypromellose.

61. (Newly Added) A composition according to claim 40, wherein the thickening agent is selected from the group consisting of polyvinylalcohol and hypromellose.

62. (Newly Added) A composition according to claim 41, wherein the thickening agent is selected from the group consisting of polyvinylalcohol and hypromellose.

63. (Newly Added) A composition according to claim 34, wherein the cyclodextrin is selected from the group consisting of dimethyl- β -cyclodextrins, trimethyl- β -cyclodextrins and sulphobutylether- β -cyclodextrin.

64. (Newly Added) A composition according to claim 35, wherein the cyclodextrin is selected from the group consisting of dimethyl- β -cyclodextrins, trimethyl- β -cyclodextrins and sulphobutylether- β -cyclodextrin.

65. (Newly Added) A composition according to claim 40, wherein the cyclodextrin is selected from the group consisting of dimethyl- β -cyclodextrins, trimethyl- β -cyclodextrins and sulphobutylether- β -cyclodextrin.

66. (Newly Added) A composition according to claim 41, wherein the cyclodextrin is selected from the group consisting of dimethyl- β -cyclodextrins, trimethyl- β -cyclodextrins and sulphobutylether- β -cyclodextrin.